文献速递传染病防控与疫情报告免疫规划

2022至2023年荷兰猴痘疫情消退的潜在因素

Factors potentially contributing to the decline of the mpox outbreak in the Netherlands, 2022 and 2023.
PubMed 文献 · Euro Surveill · 2024-01-01

2022至2023年全球猴痘疫情主要影响男男性行为者(GBMSM)。荷兰通过隔离、检疫、暴露后预防接种和初级预防接种(PPV)控制疫情。本研究描述疫情进程和疫苗接种规划,采用筛查法估算全程接种对症状性疾病的疫苗有效性(VE)为68.2%(95%CI 4.3-89.5%),未观察到高风险行为明显减少,PPV不太可能是疫情消退的驱动因素。

要点

  • 截至2023年12月31日报告1294例猴痘病例,疫情于2022年7月初达峰后急剧下降。
  • PPV于2022年7月25日启动,共接种29851剂,45.8%至少接种一剂,35.4%完成全程接种。
  • 全程接种对症状性疾病的VE估计为68.2%(95%CI 4.3-89.5%),未观察到高风险行为明显减少。

核心结论

  • PPV不太可能是疫情消退的驱动因素,因为发病率在PPV规划启动前已开始下降。
  • 行为改变的可能影响无法用现有指标证实,但数据存在局限性,妨碍解读。
  • 作者假设高风险人群中感染诱导的免疫是解释疫情消退的重要因素。

研究设计与样本

  • 观察性研究,从公共卫生服务机构收集通报病例、PPV邀请数和PPV接种剂次数据。
  • 计算PPV接种率和覆盖率,分析2022年所有就诊于性健康中心的GBMSM行为数据趋势。
  • 采用筛查法估算全程接种对症状性疾病的疫苗有效性。

主要发现

  • 截至2023年12月31日报告1294例猴痘病例,疫情于2022年7月初达峰后急剧下降。
  • PPV于2022年7月25日启动,共接种29851剂,45.8%至少接种一剂,35.4%完成全程接种。
  • 全程接种对症状性疾病的VE估计为68.2%(95%CI 4.3-89.5%)。
  • 未观察到高风险行为明显减少。

关键数值与推荐

  • 全程接种对症状性疾病的VE为68.2%(95%CI 4.3-89.5%)。
  • PPV接种率:45.8%至少接种一剂,35.4%完成全程接种。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 行为改变的可能影响无法用现有指标证实,但数据存在局限性,妨碍解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundIn 2022 and 2023, a global outbreak of mpox affected mostly gay, bisexual and other men having sex with men (GBMSM). Outbreak control in the Netherlands included isolation, quarantine, post-exposure prophylaxis vaccination and primary preventive vaccination (PPV).AimWe describe the course of the outbreak, the vaccination programme, vaccine effectiveness (VE) of full vaccination against symptomatic disease, and trends in behaviour to generate hypotheses about factors that influenced the outbreak's decline.MethodsIn this observational study, we collected data from public health services on notified cases, number of PPV invitations and PPV doses administered. We calculated PPV uptake and coverage. Trends in behavioural data of GBMSM visiting sexual health centres were analysed for all consultations in 2022. We estimated VE using the screening method.ResultsUntil 31 December 2023, 1,294 mpox cases were reported. The outbreak peaked in early July 2022 and then declined sharply. PPV started on 25 July 2022; in total 29,851 doses were administered, 45.8% received at least one dose, 35.4% were fully vaccinated. The estimated VE was 68.2% (95% CI 4.3-89.5%). We did not observe an evident decrease in high-risk behaviour.DiscussionIt is unlikely that PPV was a driver of the outbreak's decline, as incidence started to decline well before the start of the PPV programme. The possible impact of behavioural change could not be demonstrated with the available indicators, however, the data had limitations, hampering interpretation. We hypothesise that infection-induced immunity in high-risk groups was an important factor explaining the decline.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Haverkate MR, Willemstein IJ, van Ewijk CE, et al. Factors potentially contributing to the decline of the mpox outbreak in the Netherlands, 2022 and 2023. Euro Surveill. 2024. PMID: 38785092. doi:10.2807/1560-7917.ES.2024.29.21.2300608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。